SKYEPHARMA PLC
Form 6-K
February 02, 2006

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a - 16 OR 15d - 16 OF
THE SECURITIES EXCHANGE ACT OF 1934

For the month of February, 2006

SkyePharma PLC

(Translation of registrant's name into English)

SkyePharma PLC, 105 Piccadilly, London W1J 7NJ England

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40F.

Form 20-F X Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No X

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-
_____

For Immediate Release 2 Februa

SkyePharma PLC

Appointment of New Chairman and Outcome of Strategic Review

LONDON, UK, 2 February 2006 – SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces that follo candidates, it has appointed Dr Argeris ("Jerry") Karabelas as Non-executive Chairman. The Com Review has been concluded.

Dr Karabelas, aged 53, has had a distinguished career at senior levels in the global pharma Executive of Novartis Pharma and prior to that President of the North American operations of Sm executive director of Care Capital, a specialist US healthcare investment fund, and is pharmaceutical and healthcare companies including Human Genome Sciences. Dr Karabelas has been a since 2000 and his familiarity with the Company's business will enable him to make an immediate c

The Strategic Review was initiated in November 2005. As part of this process, Lehman Brother potential expressions of interest for the Company. As foreshadowed in the announcement of 1 offer for the Company as a whole that the Board feels able to recommend to shareholders. Howeve interests of returning the Company to sustainable profitability in the shortest possible time, and pulmonary products and divest the injectable business interests, for which a number of p during the Strategic Review. Any such divestment will be subject to approval by shareholders.

The injectables business, primarily located in San Diego, consists of two marketed products, and Depodur® for the treatment of post-surgical pain, and a pipeline of projects in various controlled-release injectable formulations of a number of biological products and DepoBup formulation of the local anaesthetic bupivacaine for the control of post-operative pain. De development and will commence Phase III trials shortly. It has been licenced to Mundipharm American and Japan and to Maruho for Japan. The Board remains convinced that DepoBupivacaine medical need and has major commercial potential. However the Board is conscious of the fact that development would be required to maximise the potential of DepoBupivacaine and of the bio investment, together with the associated investment in manufacturing capacity, would not o Company's current resources but also impact the Company's profitability for several years.

The Company believes that the injectables business is a valuable asset and the funds raised by enhance the core oral and pulmonary business, including accelerating the development of certain business will consist of the oral and pulmonary products business, with development based in Mu Muttenz and in Lyon, France. There are seven marketed oral and pulmonary products, including Pax a number of late-stage products that are close to the market. The pipeline includes SkyePharm Flutiform , a combination asthma product that will enter Phase III development in the next portfolio and pipeline will be disclosed at the Company's R&D Days. These had to be postponed d dates will be announced shortly.

Dr Karabelas said: "I am honoured to take on the role of Chairman and look forward impleme particularly given my background in the development of oral and respiratory products. I am ver confident I can make an important contribution to its future success. I also relish the oppo confidence."

The conclusion of the Strategic Review and the fact that the Company is no longer in discussio with any party concerning an offer for the Company as a whole means that the Company is no long the UK Takeover Panel. Further announcements will be made in due course about the ongoing in executive management team.

For further information please contact:

SkyePharma PLC
Michael Ashton, Chief Executive +44 207 491 1777
Peter Laing, Director of Corporate Communications +44 207 491 5124
Sandra Haughton, US Investor Relations +1 212 753 5780

Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court

About SkyePharma

SkyePharma PLC develops pharmaceutical products benefiting from world-leading drug delivery te
and more effective drug formulations. There are now eleven approved products incorporating Skye
oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabi
www.skyepharma.com.

Certain statements in this news release are forward-looking statements and are made in reliance
U.S. Private Securities Litigation Act of 1995. Although SkyePharma believes that the expectatio
statements are reasonable, it can give no assurance that these expectations will materialize. B
risks and uncertainties, actual results may vary significantly from those expressed or impli
based upon a number of factors, which are described in SkyePharma's 20-F and other documents on
cause differences between actual results and those implied by the forward-looking statements c
without limitation, risks related to the development of new products, risks related to obtainin
for existing, new or expanded indications of existing and new products, risks related to SkyePh
on a large scale or at all, risks related to SkyePharma's and its marketing partners' ability
maintain or expand market share in the face of changes in customer requirements, competition an
to regulatory compliance, the risk of product liability claims, risks related to the ownership
risks related to SkyePharma's ability to manage growth. SkyePharma undertakes no obliga
forward-looking statement to reflect events or circumstances after the date of this release.

END

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

SkyePharma PLC

By: /s/ Douglas Parkhill

Name: Douglas Parkhill
Title: Company Secretary

Date: February 02, 2006